NCT05803616View on ClinicalTrials.gov

Liquid Biopsy to Enable Diagnostics and Monitoring for Immune-mediated Lymphoproliferative Disorders

RecruitingOBSERVATIONAL
Enrollment

20

Participants

Timeline

Start Date

May 23, 2022

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2025

Conditions
Lymphoproliferative DisordersLymphoproliferative Disorder Following Transplantation
Interventions
DIAGNOSTIC_TEST

Liquid biopsy

ctDNA measured in the plasma and analyse by next generation sequencing (NGS) for minimal residual disease (MRD)

Trial Locations (6)

1205

RECRUITING

Hôpitaux Universitaires de Genève (HUG), Geneva

Unknown

NOT_YET_RECRUITING

Basel University Hospital, Basel

NOT_YET_RECRUITING

Oncology Institute of Southern Switzerland, Bellinzona

RECRUITING

Inselspital, Bern

NOT_YET_RECRUITING

Kantonsspital, Sankt Gallen

NOT_YET_RECRUITING

University Hospital Zürich, Zurich

All Listed Sponsors
lead

University Hospital, Geneva

OTHER